Related references
Note: Only part of the references are listed.Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids
Ali S. Abdelhameed et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2022)
Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids
Ali S. Abdelhameed et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2021)
Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
Mohamed W. Attwa et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation
Ali S. Abdelhameed et al.
ROYAL SOCIETY OPEN SCIENCE (2019)
Investigation of metabolic stability of the novel ALK inhibitor brigatinib by Liquid chromatography tandem mass spectrometry
Hany W. Darwish et al.
CLINICA CHIMICA ACTA (2018)
Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS
Mohamed W. Attwa et al.
CLINICA CHIMICA ACTA (2018)
A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate
Mohamed W. Attwa et al.
EUROPEAN JOURNAL OF MASS SPECTROMETRY (2018)
LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate
Sawsan M. Amer et al.
CHEMISTRY CENTRAL JOURNAL (2017)
Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation
Sawsan M. Amer et al.
CHEMISTRY CENTRAL JOURNAL (2017)
Rapid micellar HPLC analysis of loratadine and its major metabolite desloratadine in nano-concentration range using monolithic column and fluorometric detection: application to pharmaceuticals and biological fluids
Fathalla Belal et al.
CHEMISTRY CENTRAL JOURNAL (2016)
A new spectrofluorimetric assay method for vandetanib in tablets, plasma and urine
Hany W. Darwish et al.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH (2016)
Vandetanib as a potential new treatment for ER negative breast cancers
Elisabetta Marangoni et al.
CANCER RESEARCH (2015)
Fast quantitative analysis of four tyrosine kinase inhibitors in different human plasma samples using three-way calibration-assisted liquid chromatography with diode array detection
Shou-Xia Xiang et al.
JOURNAL OF SEPARATION SCIENCE (2015)
Validation of a high-performance liquid chromatographic ultraviolet detection method for the quantification of vandetanib in rat plasma and its application to pharmacokinetic studies
Hongjun Lin et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2014)
Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials
Yong-Ying Xiao et al.
CLINICAL ONCOLOGY (2013)
High Throughput Quantitative Bioanalytical LC/MS/MS Determination of Gemifloxacin in Human Urine
Adnan A. Kadi et al.
JOURNAL OF CHEMISTRY (2013)
Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects
Paul Martin et al.
CLINICAL THERAPEUTICS (2012)
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)
Feng Bai et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2011)
PHASE I STUDY OF VANDETANIB WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Jan Drappatz et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues
JA Zirrolli et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2005)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
SN Holden et al.
ANNALS OF ONCOLOGY (2005)
A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
KD Miller et al.
CLINICAL CANCER RESEARCH (2005)
Share Paper
